Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
…
continue reading
Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
1
Patient Case: Tailoring First Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
1
Navigating Treatment-Related Adverse Effects in LAG3 Combination ICI Therapy for Metastatic Melanoma
Host: Allison Betof Warner, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
Host: Allison Betof Warner, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
1
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Host: Allison Betof Warner, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.…
…
continue reading
Host: Robert F. Kushner, MD Host: Donna Ryan, MD Host: Christopher D. Still, DO, FACN, FACP, FTOS Obesity experts review obesity management strategies and provide insight on best practices for implementation in a primary care setting.
…
continue reading
Host: Jonathan Chung, MD Host: Seth Kligerman, MD Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach.
…
continue reading
Host: Richard Lafayette, MD, FACP Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.
…
continue reading
1
Multidisciplinary Approach to Diagnosing and Managing Indolent Systemic Mastocytosis: The Changing Landscape
Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD Guest: Matthew J. Hamilton, MD Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape i…
…
continue reading
Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of …
…
continue reading
Guest: John Berk, MD Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for ea…
…
continue reading
Guest: John Berk, MD Guest: Noel Dasgupta, MD, FACC Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flag…
…
continue reading
Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identif…
…
continue reading
Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and re…
…
continue reading
Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identif…
…
continue reading
Guest: Sami Khella, MD Guest: Marcia Waddington-Cruz, MD, PhD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identif…
…
continue reading
Guest: John Berk, MD Guest: Sami Khella, MD Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for ea…
…
continue reading
Guest: Noel Dasgupta, MD, FACC Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection…
…
continue reading
Host: Marianna Fontana, MD The HELIOS trials, a groundbreaking phase 3 program, are investigating the potential of vutrisiran, an RNA interference (RNAi) therapy, to combat both hereditary and wild-type ATTR amyloidosis. Building on a successful phase 1 study demonstrating vutrisiran's safety and effectiveness in reducing serum TTR, HELIOS is pavin…
…
continue reading
1
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
Host: Jeffrey V. Matous, MD Guest: Donna Catamero, NP Guest: Ajai Chari, MD GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important …
…
continue reading
Host: Carl Regillo, MD Guest: Jennifer I. Lim, MD, FARVO What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as they discuss the biomarkers of Ang-2 and VEGF-A suppression. Hear how to achieve earlier and faster fluid resolution in both neo…
…
continue reading
Host: Omer Abdul Hamid, MD Guest: Nancy Kuntz, MD Guest: Migvis Monduy, MD There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they …
…
continue reading
Host: Arshad M. Khanani, MD, MA Guest: Theodore Leng, MD, MS Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on c…
…
continue reading
Host: Tauseef Ali, MD, FACG, AGAF Host: Sabina Ali, MD Host: Neil Nandi, MD, FACP Host: Tina Aswani-Omprakash, MPH A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the importance of providing culturally competent care.…
…
continue reading
Host: Dmitry M. Yaranov, MD During the clinical course of heart failure, even with guideline directed medical therapy, many patients still experience symptoms that negatively impact their quality of life. Baroreflex activation therapy, or BAT, is an FDA approved therapy for patients with heart failure with reduced ejection fraction that has been sh…
…
continue reading
1
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
Host: Deborah Siegal, MD, MSc, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help cli…
…
continue reading
Host: Deborah Siegal, MD, MSc, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help cli…
…
continue reading
Host: Scott Kaatz, DO, MSc, FACP, SFHM Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help c…
…
continue reading
Host: Scott Kaatz, DO, MSc, FACP, SFHM Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help c…
…
continue reading
Host: Bruce L. Davidson, MD, MPH Host: Victor F. Tapson, MD Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of t…
…
continue reading
Host: Victor F. Tapson, MD Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians ef…
…
continue reading
Host: Bruce L. Davidson, MD, MPH Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinici…
…
continue reading
Host: Bruce L. Davidson, MD, MPH Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinici…
…
continue reading
Host: Alfonso J. Tafur, MD, MS, MBA, RPVI Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the compon…
…
continue reading
Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels…
…
continue reading
Host: Alfonso J. Tafur, MD, MS, MBA, RPVI Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to hel…
…
continue reading
Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels…
…
continue reading
Host: Anne Marie Morse, DO, FAASM One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be …
…
continue reading
Host: Seema Khosla, MD, FCCP, FAASM One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can b…
…
continue reading
Host: Michael E. Yurcheshen, MD, FAASM One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and ca…
…
continue reading
Host: Kevin Trice, MD One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily imple…
…
continue reading
Host: Alcibiades J. Rodriguez, MD, FAASM One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and …
…
continue reading
1
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Host: Meghan Mooradian, MD This Patient Clinician Connection CME activity, led by Dr. Meghan Mooradian, focuses on the use of adjuvant immunotherapy in early-stage melanoma. The activity aims to educate clinicians on the role of immunotherapy in reducing the risk of disease recurrence post-surgery, particularly in patients with resected stage IIB t…
…
continue reading
Guest: Durga Borkar, MD, MMCi Guest: Diana Do, MD Guest: Peter K. Kaiser, MD The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include rece…
…
continue reading
Host: Arun B. Jesudian, MD Host: Robert Rahimi, MD, MSCR Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorient…
…
continue reading
Host: Robert Rahimi, MD, MSCR Host: Arun B. Jesudian, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorient…
…
continue reading
Host: Patricia P. Bloom, MD Host: Robert Rahimi, MD, MSCR Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorien…
…
continue reading
Host: Patricia P. Bloom, MD Presenting a major burden on our healthcare system, hepatic encephalopathy (HE) is a neurologic disorder that frequently affects individuals with chronic and acute liver disease. Characterized by a broad range of neurologic and psychological symptoms, including cognitive impairment, disorientation, sleep disturbances, an…
…
continue reading